drugset / Trial / NCT00332917

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

NCT00332917

Phase 3 Completed 224 enrolled Solvay Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.001 trial

Timeline

Start
2007-02
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Pardoprunox Small molecule

Indications